logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Editas Medicine, Inc.


USPTO Granted Patents = 53



Trademarks = 7

Forward Citations = 194

Loading Chart...
Loading Chart...

75 inventors (with patents filed for the assignee):

goldMedal David A Bumcrot (14 out of 54 patents)

silverMedal Morgan Lee Maeder (14 out of 14 patents)

bronzeMedal Hariharan Jayaram (12 out of 12 patents)

4.  Ari E Friedland (11 out of 12 patents)

5.  Barrett Ethan Steinberg (10 out of 23 patents)

6.  Cecilia Cotta-Ramusino (8 out of 8 patents)

7.  Shen Shen (7 out of 8 patents)

8.  Jennifer Leah Gori (5 out of 7 patents)

9.  Feng Zhang (4 out of 185 patents)

10.  Deborah Palestrant (4 out of 8 patents)

11.  Jordi Mata-Fink (4 out of 26 patents)

12.  Edgardo Rodriguez (4 out of 9 patents)

13.  Alexis Borisy (4 out of 14 patents)

14.  John Zuris (4 out of 14 patents)

15.  Penrose O'Donnell (4 out of 4 patents)


Core Competencies:
CRISPR-Cas9
Gene Editing
Immunotherapy
Nuclease Cleavage
Homology Directed Repair
Guide RNA
Exon-Skipping
Chromosomal Rearrangements
Cancer Treatment
Retinal Dystrophy
Hemoglobinopathies
Cystic Fibrosis

53 patents:

1. 12698489 - METHODS, COMPOSITIONS AND COMPONENTS FOR CRISPR-CAS9 EDITING OF TGFBR2 IN T CELLS FOR IMMUNOTHERAPY (2026-08-04),
2. 12545912 - CRISPR/Cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa (2026-02-10),
3. 12460231 - Crispr/CAS-related methods and compositions for treating primary open angle glaucoma (2025-11-04),
4. 12359223 - Systems and methods for modulating chromosomal rearrangements (2025-07-15),
5. 12338436 - Synthetic guide molecules, compositions and methods relating thereto (2025-06-24),
6. 12331328 - CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome (2025-06-17),
7. 12325854 - Crispr-CPF1-related methods, compositions and components for cancer immunotherapy (2025-06-10),
8. 12297466 - Engineered Cas9 nucleases (2025-05-13),
9. 12286727 - Assessing nuclease cleavage (2025-04-29),
10. 12264331 - Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA (2025-04-01),
11. 12234449 - CRISPR/Cas-related methods and compositions for treating Leber's congenital amaurosis 10 (LCA10) (2025-02-25),
12. 12214055 - Systems and methods for treating hyper-igm syndrome (2025-02-04),
13. 12201699 - Compositions and methods for promoting homology directed repair (2025-01-21),
14. 12110545 - Methods of assessing nuclease cleavage (2024-10-08),
15. 12049651 - Cas9 fusion molecules, gene editing systems, and methods of use thereof (2024-07-30),
Editas Medicine, Inc. is a pioneering biotechnology company based in Cambridge, MA, specializing in CRISPR gene editing technologies. The organization focuses on developing transformative therapies that harness the power of CRISPR-Cas9 for precise genetic modifications. Their research encompasses various core technology topics, including gene editing, immunotherapy, and innovative approaches like homology directed repair and exon-skipping. Editas aims to address genetic diseases through advanced therapeutic solutions, positioning itself at the forefront of genetic medicine.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Editas Medicine, Inc.
53 Patents

#49 in Cambridge, MA

#377 in Massachusetts

#6,661 in US

#13,309 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Editas Medicine, Inc.

Forward Citations = 194

75 inventors:

goldMedal David A Bumcrot (14 out of 54 patents)

silverMedal Morgan Lee Maeder (14 out of 14 patents)

bronzeMedal Hariharan Jayaram (12 out of 12 patents)

4.  Ari E Friedland (11 out of 12 patents)

5.  Barrett Ethan Steinberg (10 out of 23 patents)

Please report any incorrect information to [email protected]
Loading…